Evidence map›Paper›PMID 38617836›Full record

ArticleJournal of clinical tuberculosis and other mycobacterial diseases2024

Monocytes predict prognosis and successful treatment in older patients with miliary tuberculosis.

Yusuke Shima, Takahiro Masuda, Nanako Miwa, Yoko Kida, Rikiya Koketsu, Hiroshi Kamiryo, Toshiyasu Sakurai, Kimihide Tada

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical tuberculosis and other mycobacterial diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yusuke ShimaDepartment of Respiratory Medicine, Kobe City Nishi-Kobe Medical Center, Kobe, Japan.
Takahiro MasudaDepartment of Respiratory Medicine, Kobe City Nishi-Kobe Medical Center, Kobe, Japan.
Nanako MiwaDepartment of Respiratory Medicine, Kobe City Nishi-Kobe Medical Center, Kobe, Japan.
Yoko KidaDepartment of Respiratory Medicine, Kobe City Nishi-Kobe Medical Center, Kobe, Japan.
Rikiya KoketsuDepartment of Respiratory Medicine, Kobe City Nishi-Kobe Medical Center, Kobe, Japan.
Hiroshi KamiryoDepartment of Respiratory Medicine, Kobe City Nishi-Kobe Medical Center, Kobe, Japan.
Toshiyasu SakuraiDepartment of Respiratory Medicine, Kobe City Nishi-Kobe Medical Center, Kobe, Japan.
Kimihide TadaDepartment of Respiratory Medicine, Kobe City Nishi-Kobe Medical Center, Kobe, Japan.
Kobe City Nishi-Kobe Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The increasing number of patients with miliary tuberculosis (MTB) is a concern in an aging society because of its high mortality rate. Several prognostic biomarkers for MTB have been identified; however, the predictive ability of monocytes as biomarkers remains unknown. This study demonstrates the usefulness of monocytes as prognostic biomarkers for MTB. Materials and methods: We retrospectively compared the clinical findings of 52 patients with MTB hospitalized between April 2013 and October 2021. The predictive ability of biomarkers for 3-month prognosis and their cutoff values were calculated. Survival times and longitudinal changes in monocytes after initiating treatment were compared. Results: A smaller number of monocytes (#M), higher lymphocyte-monocyte ratio (LMR), higher neutrophil-monocyte ratio, and poorer performance status were associated with death within 3 months. #M was an independent prognostic factor. #M and LMR exhibited the highest predictive performance compared to others using receiver operating characteristic curve analysis (area under the curve = 0.86 and 0.85, respectively). Survival time was shorter in patients with #M ≤ 200 cells/μL and LMR > 2.5. Rapidly increasing #M after treatment was related to better prognosis in patients with #M ≤ 200 cells/μL at diagnosis. Conclusions: #M at diagnosis and longitudinal changes in monocytes are related to MTB prognosis.

Indexed as

InflammationLymphocyte-monocyte ratioMiliary tuberculosisMonocyteNeutrophil-monocyte ratioPrognostic biomarker

Identifiers

PMID38617836
PMCPMC11010963
OpenAlexW4393997576

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.